More bad news for Novavax’s RSV vaccine, this time in Europe

Sara Gilgore
More bad news for Novavax’s RSV vaccine, this time in Europe

Novavax Inc. has suffered yet another major setback in its quest to get its respiratory syncytial virus vaccine to market: European regulators aren’t on board. The Gaithersburg company expects to receive notice that the European Medicines Agency won’t be granting RSV vaccine ResVax a conditional marketing authorization pathway in the European Union, “based on the data package provided under the scientific advice request,” Novavax (NASDAQ: NVAX) disclosed in Securities and Exchange Commission filings Monday.